Clinical Report: Bipolar Disorder Prevalence and Risk in Multiple Sclerosis

Overview

This systematic review and meta-analysis evaluated the prevalence of bipolar disorder (BD) in individuals with multiple sclerosis (MS) and assessed the association between MS and BD risk. Findings indicate a notable prevalence of BD among people with MS (PwMS) and suggest an increased risk of BD in this population compared to controls.

Background

Multiple sclerosis (MS) is a chronic autoimmune disease causing inflammatory demyelination in the central nervous system, leading to diverse neurological symptoms and disability. Neuropsychiatric disorders, including bipolar disorder (BD), are common comorbidities in PwMS and can worsen quality of life and disease outcomes. BD encompasses mood disorders characterized by manic or hypomanic episodes and major depression, with pathophysiology involving white matter abnormalities and neural circuit dysfunction. Understanding the prevalence and risk of BD in MS is critical for optimizing treatment and prognosis.

Data Highlights

The meta-analysis synthesized data from multiple studies reporting BD prevalence, odds ratios (OR), and hazard ratios (HR) in PwMS. The prevalence of BD in PwMS ranged from 0% to 16.2% across studies. Random-effects models were used to calculate pooled estimates, accounting for heterogeneity. Risk of bias was assessed using the Newcastle–Ottawa Scale. Statistical heterogeneity was evaluated with Cochran’s Q and I² statistics, and publication bias was assessed via funnel plots and Begg’s and Egger’s tests.

Key Findings

• The pooled prevalence of bipolar disorder among people with multiple sclerosis is significant, with reported rates varying widely across studies.
• Individuals with MS have an increased odds ratio and hazard ratio for developing BD compared to non-MS populations, indicating a higher risk.
• White matter abnormalities common to both MS and BD may underlie the neuropsychiatric comorbidity observed.
• BD in PwMS is associated with reduced medication adherence and poorer quality of life, complicating disease management.
• Diagnosis of BD in PwMS is challenging due to overlapping symptoms and effects of disease-modifying therapies.
• Methodological heterogeneity exists across studies, but sensitivity analyses support the robustness of the association between MS and BD.

Clinical Implications

Clinicians should maintain a high index of suspicion for bipolar disorder in patients with multiple sclerosis, given the increased prevalence and risk. Early identification and management of BD in PwMS are essential to improve medication adherence, quality of life, and overall prognosis. Careful differentiation between neuropsychiatric symptoms and MS manifestations is necessary to optimize treatment strategies.

Conclusion

This systematic review and meta-analysis highlight a significant comorbidity of bipolar disorder in individuals with multiple sclerosis, underscoring the need for integrated neurological and psychiatric care. Recognizing and addressing BD in PwMS can enhance clinical outcomes and patient quality of life.

References

1. Systematic Review Authors/2025 -- An Updated Systematic Review and Meta-Analysis of Bipolar Disorder in Individuals with Multiple Sclerosis